Semaglutide or tirzepatide? Let's cut to it: both are real, both are prescriptions, and one tended to win on weight loss.

The short version

Both are legit, approved weight-loss drugs. The headline difference: tirzepatide hits two gut hormones, semaglutide hits one, and in trials, tirzepatide tended to drive more weight loss. But which fits you is a doctor's decision, not a leaderboard. And both are prescription-only for a reason.

The head-to-head

FactorSemaglutideTirzepatide
Brand namesWegovy, OzempicZepbound, Mounjaro
How it worksOne target (GLP-1)Two targets (GLP-1 + GIP)
Weight loss in trialsStrongTended to be greater head-to-head
StatusApproved, prescription-onlyApproved, prescription-only

Semaglutide: the one that started the wave

Semaglutide is the GLP-1 that made this whole category famous: Ozempic for diabetes, Wegovy for weight. It mimics a gut hormone that curbs appetite, and the weight-loss evidence is strong. It's a real, approved medicine. It's also prescription-only, with side effects, and it's not something you self-source off a website.

Tirzepatide: the double-target one

Tirzepatide is the newer one, and it does something semaglutide doesn't: it hits two hormone systems (GLP-1 and GIP) instead of one. In head-to-head trials, that tended to translate into more weight loss on average. Impressive on paper. But 'more weight loss' isn't a free win. More effect can mean more side effects for some people, and that trade-off is exactly what a doctor is for.

What's next: retatrutide

You'll hear buzz about retatrutide, a next-gen drug hitting three targets, showing big numbers in trials. Keep it in perspective: it's still in clinical trials, not approved, not on shelves. Promising, not proven. Anyone selling it to you right now is selling you something they shouldn't.

What's true

  • Both are approved, prescription-only, and genuinely drive weight loss
  • Tirzepatide hits two targets and tended to more weight loss in trials
  • A doctor decides which one (if either) fits you

What's a myth

  • 'Tirzepatide is always better': more effect isn't automatically better for you
  • 'You can safely buy a research version to save money': you can't verify it
  • 'Retatrutide is available now': it's still in trials

The honest verdict

Both are the real deal. Tirzepatide tended to edge out semaglutide on weight loss in trials thanks to its dual-target design, but the right pick depends on your side effects, cost, and health, and that's a doctor's call. Retatrutide is one to watch, not to buy. And grey-market versions of any of them are a hard skip.

What this does not mean

  • This doesn't mean tirzepatide is the right choice for everyone. 'More weight loss on average' isn't a personal prescription.
  • This doesn't mean you can safely buy a cheaper 'research' version. You can't verify grey-market vials.
  • This is general info, not medical advice. A doctor decides which drug, if any, fits you.